Home > Clinical Development > ONX 0801

ONX 0801

ONX 0801, a thymidylate synthase (TS) inhibitor, is a novel targeted compound designed to work by combining two proven approaches to improving outcomes for cancer patients.  These include receptor-mediated targeting of tumor cells and inhibition of thymidylate synthase, a key enzyme involved in cell growth and division.   ONX 0801 is believed to target cells through the alpha-folate receptor, which is primarily located on the surface of some kinds of tumor cells and is overexpressed in a number of cancer types with significant unmet needs, including ovarian and lung cancer.  After ONX 0801 enters the cell via this receptor, the compound inhibits, or switches off, TS.  ONX 0801 is believed to be distinct from currently marketed TS inhibitors, such as pemetrexed, 5 fluorouracil (5-FU), and raltitrexed, due to its selective uptake by the alpha-folate receptor. ONX 0801 is currently in Phase 1 clinical development in patients with solid tumors.

Stock Quote (update every 15 minutes): As of 4:00pm - 5/20/2011

  • Symbol
    ONXX
  • Last
    43.71 +0.22
  • Open
    43.46
  • High
    43.81
  • Low
    42.49
  • Volume
    1139204